Efficacy and safety of azathioprine versus mycophenolate mofetil in chronic actinic dermatitis in skin of color: results of a randomized controlled trial
International Journal of Dermatology · 2025
DOI: 10.1111/ijd.17412 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Dermatology, 2025. Verfasst von Sanjeev Handa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Hauptthemen laut MEDLINE: Azathioprine, Mycophenolic Acid, Photosensitivity Disorders, Immunosuppressive Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
Introduction
Chronic actinic dermatitis (CAD) is an immunologically mediated photodermatosis that has been effectively treated with azathioprine and mycophenolate mofetil (MMF) in uncontrolled studies. We conducted a prospective randomized controlled trial to compare the efficacy and safety of azathioprine and MMF in CAD treatment, aiming to address existing evidence gaps. Materials and methods Consecutive CAD patients were randomized into two groups: azathioprine (Group A) or MMF (Group B) for 12 weeks. Primary outcomes included Eczema Area and Severity Index (EASI) and Dermatology Life Quality Index (DLQI) at baseline and Week 12. Secondary outcomes included various clinicodemographic factors predictive of treatment response, defined at least a 75% reduction in EASI score (EASI75) by Week 12.
Results
The median (IQR) percentage reduction in EASI at 12 weeks was higher in Group B than in Group A [78.3% (75.0–83.30%) vs. 68.3% (31.2–80.10%), P = 0.034]. Baseline DLQI scores indicated a moderate impact on quality of life, with significant reductions by Week 12 in both groups and no intergroup differences at baseline ( P = 0.291) or Week 12 ( P = 0.599). Overall, 23 patients were classified as non‐responders, with more extended illness duration ( P = 0.026) and outdoor occupations ( P = 0.042) associated with poorer responses. Adverse effects were consistent with known profiles, with one patient discontinuing azathioprine due to hypersensitivity.
Conclusion
Our study highlights the efficacy and safety of azathioprine and MMF in CAD treatment, with MMF showing superior outcomes. However, further research is warranted to explore emerging therapies and prognostic factors in CAD management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
ORCID-Profile: Hitaishi Mehta, Dipankar De
Zitieren
APA
Handa, S., Mehta, H., Bishnoi, A., Raj, D., & De, D. (2025). Efficacy and safety of azathioprine versus mycophenolate mofetil in chronic actinic dermatitis in skin of color: results of a randomized controlled trial. International Journal of Dermatology. https://doi.org/10.1111/ijd.17412
Vancouver
Handa S, Mehta H, Bishnoi A, Raj D, De D. Efficacy and safety of azathioprine versus mycophenolate mofetil in chronic actinic dermatitis in skin of color: results of a randomized controlled trial. International Journal of Dermatology. 2025. doi:10.1111/ijd.17412
BibTeX
@article{Handa2025,
author = {Handa, Sanjeev and Mehta, Hitaishi and Bishnoi, Anuradha and Raj, Dinesh and De, Dipankar},
title = {Efficacy and safety of azathioprine versus mycophenolate mofetil in chronic actinic dermatitis in skin of color: results of a randomized controlled trial},
journal = {International Journal of Dermatology},
year = {2025},
doi = {10.1111/ijd.17412}
}
EUVIMED